ABSTRACT
Background
Non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) may be eligible for targeted immunotherapies. Literature does not currently estimate direct costs associated with this population. We aimed to identify the total direct costs associated with PD-L1 positive stage IV NSCLC treated with immunotherapy.
Methods
Using progression-free survival, overall survival, treatment-related serious adverse events leading to hospitalization, and end-of-life resource use, we estimated costs for one year of treatment in this incidence-based study. Data were obtained from online databases, guideline recommendations, clinical trials, and proprietary market share data. We summed the costs of PD-L1 immunohistochemistry (IHC) tests, drugs, hospitalizations, and deaths associated with treatment, estimating the overall cost-of-illness for stage IV NSCLC in the United States in 2021.
Results
An estimated 22,711 patients in the US had stage IV NSCLC treated with PD-L1 immunotherapy in 2021. Total 2021 costs were estimated at $3.01 billion. Drugs (including immunotherapy, second-line chemotherapy, and other oncology drugs) accounted for nearly 97% ($2.91 billion) of the total.
Conclusions
PD-L1 positive stage IV NSCLC treatment is a costly condition with annual direct medical costs of $3.01 billion. The primary cost driver was immunotherapy, making up 74.6% of the total cost.
Acknowledgments
The authors wish to thank and acknowledge Roche for providing summary data on PD-L1 IHC diagnostic assay market share from the Flatiron database.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.